Amneal Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300VV176ZO5WQHZ61
    ISIN
    US03168L1052 (AMRX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    45 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    7 / 7

    Profile

    Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Read full profile

    Fundamentals

    Net revenue
    €2.43B
    Gross margin
    37.7%
    EBIT
    €320.98M
    EBIT margin
    13.2%
    Net income
    €2.88M
    Net margin
    0.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.72B +11.8% €253.45M +8,704.4%
    €2.95B +8.4% €314.50M +24.1%
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Kiely John N/A -32K $9.23 -$295.36K
    Shah Nikita Executive Vice President -121K $9.65 -$1.17M
    BOYER ANDREW S Executive Vice President -279K $9.38 -$2.62M
    Konidaris Tasos Executive Vice President & CFO -500K $9.33 -$4.66M
    Shah Nikita Executive Vice President -72K $9.29 -$666.04K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 625K $5.23M -62K Sell

    Earnings Calls

    Latest earnings call: May 3, 2024 (Q1 2024)

    Add to watchlist

    Notifications